CC-98633 by Bristol-Myers Squibb for Relapsed Multiple Myeloma: Likelihood of Approval

CC-98633 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Relapsed Multiple Myeloma.

Your Brain on Mars; Differential Dementia Diagnosis by AI; ALS Gene Identified

More work is needed to mitigate the effects of long spaceflights on the central nervous system before humans travel to Mars, experts concluded. (Lancet Neurology)

July 10, 2024

Over 47,000 heat-related deaths estimated to have occurred in Europe in 2023

Researchers projected age- and sex-specific heat-related deaths across Europe by 2023. They also calculated the death load saved via social adaptation to increasing temperatures since

August 14, 2024

As kids, they underwent a common test for UTIs. As adults, it haunts them as a traumatic ‘nightmare’

This story contains descriptions of an invasive medical procedure and mention of sexual assault. It’s been nearly three decades since Shelby Smith underwent a series

September 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.